MALCOLM BRENNER to Adoptive Transfer
This is a "connection" page, showing publications MALCOLM BRENNER has written about Adoptive Transfer.
Connection Strength
1.599
-
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6.
Score: 0.343
-
Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics. Curr Pharm Des. 2009; 15(4):424-9.
Score: 0.283
-
Chimeric T-cell receptors for the targeting of cancer cells. Acta Haematol. 2003; 110(2-3):154-9.
Score: 0.187
-
Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29.
Score: 0.101
-
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
Score: 0.096
-
Genetic modification of T cells. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S15-20.
Score: 0.081
-
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703.
Score: 0.076
-
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402.
Score: 0.072
-
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood. 2005 Mar 15; 105(6):2436-42.
Score: 0.053
-
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27.
Score: 0.052
-
Use of gene marking technologies in oncology. Forum (Genova). 1998 Oct-Dec; 8(4):342-53.
Score: 0.035
-
Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
Score: 0.030
-
Gene-marking and haemopoietic stem-cell transplantation. Blood Rev. 1995 Dec; 9(4):220-5.
Score: 0.029
-
Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220.
Score: 0.025
-
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res. 2014 Jan 01; 20(1):131-9.
Score: 0.025
-
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010 Nov 25; 116(22):4700-2.
Score: 0.020
-
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35.
Score: 0.019
-
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91.
Score: 0.019
-
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802.
Score: 0.016
-
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006 Dec 01; 108(12):3890-7.
Score: 0.015
-
Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81.
Score: 0.013
-
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002 Dec 01; 100(12):4059-66.
Score: 0.011